Stocks Health care FULC
NASDAQ · Health careFulcrum Therapeutics, Inc. (FULC)
It posted a net loss of $85M. In fiscal 2025 capital spending exceeded operating cash flow by $60.4M. At June 30, 2026 it held $48.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 30, 2026.
What Fulcrum Therapeutics, Inc. does
Fulcrum Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker FULC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$74.9M | -$1.18 | -$60.4M |
| 2024 | $80M | -$9.7M | -$0.16 | -$2.5M |
| 2023 | $2.8M | -$97.3M | -$1.59 | -$91.5M |
| 2022 | $6.3M | -$109.9M | -$2.44 | -$99M |
| 2021 | $19.2M | -$80.8M | -$2.29 | -$80.2M |
| 2020 | $8.8M | -$70.8M | -$2.79 | -$55M |
Latest SEC filings
What Fulcrum Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 2, 2026
- August 17, 2026Form 425 filing 425
- August 17, 2026Form 425 filing 425
- August 17, 2026Form 425 filing 425
- August 17, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026
Questions about FULC
What does Fulcrum Therapeutics, Inc. do?
Fulcrum Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker FULC.
Is Fulcrum Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $85M.
When did Fulcrum Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 30, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the merger registration from September 2, 2026.
Similar companies
Follow FULC
Get an email when Fulcrum Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow FULC: get an email when it filesWhere the numbers come from
Financial figures are the values Fulcrum Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.